PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets - PubMed (original) (raw)

Meta-Analysis

PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets

Siying He et al. BMC Cancer. 2020.

Abstract

Absract: BACKGROUND: Several studies have investigated the associations between the podocalyxin-like protein (PODXL) expression quantity or locations and cancers survival, but the results were far from conclusive. Therefore, we proceeded a meta-analysis on PODXL in various human cancers to find its prognostic value and followed confirmation using the TCGA datasets.

Methods: We performed a systematic search, and 18 citations, including 5705 patients were pooled in meta-analysis. The results were verified with TCGA datasets.

Results: Total eligible studies comprised 5705 patients with 10 types of cancer. And the result indicated that PODXL high-expression or membrane-expression were significantly related to poor overall survival (OS). However, subgroup analysis showed a significant association between high expressed PODXL and poor OS in the colorectal cancer, pancreatic cancer, urothelial bladder cancer, renal cell carcinoma and glioblastoma multiforme. Then, we validated the inference using TCGA datasets, and the consistent results were demonstrated in patients with pancreatic cancer, glioblastoma multiforme, gastric cancer, esophageal cancer and lung adenocarcinoma.

Conclusion: The result of meta-analysis showed that high expressed PODXL was significantly linked with poor OS in pancreatic cancer and glioblastoma multiforme, but not in gastric cancer, esophageal cancer or lung adenocarcinoma. And the membrane expression of PODXL might also associate with poor OS. PODXL may act as tumor promotor and may serve as a potential target for antitumor therapy.

Keywords: Cancer; Meta-analysis; Podocalyxin-like protein; Prognosis; TCGA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1

Flow diagram of study selection

Fig. 2

Forest plot of studies evaluating HRs of PODXL expression and the prognosis of cancer patients. a High expressed PODXL and the OS; b high expressed PODXL and the DFS; c high expressed PODXL and the CSS; d membrane expressed PODXL and the OS

Fig. 3

Sensitivity analysis of this meta-analysis. a OS of PODXL expression levels; b DFS of PODXL expression levels; c CSS of PODXL expression levels; d OS of PODXL expression locations

Fig. 4

Begg’s funnel plots for the studies involved in the meta-analysis. a OS of PODXL expression levels; b DFS of PODXL expression levels; c CSS of PODXL expression levels; d OS of PODXL expression locations

Fig. 5

Kaplan-Meier survival curves for cancer patients based on TCGA datasets. a glioblastoma multiforme; b kidney renal papillary cell carcinoma; c pancreatic adenocarcinoma; d kidney renal clear cell carcinoma; e uterine corpus endometrial carcinoma

Fig. 6

Mechanism prediction of PODXL-related genes with bioinformatics. a The protein-protein interaction network of PODXL-related genes. The lines represented the interaction between the nodes. b The functional enrichment analysis of PODXL-related genes

References

1. Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, et al. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 2004;64(15):5068–5073. doi: 10.1158/0008-5472.can-04-0240. - DOI - PubMed
1. McNagny KM, Pettersson I, Rossi F, Flamme I, Shevchenko A, Mann M, et al. Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J Cell Biol. 1997;138(6):1395–1407. doi: 10.1083/jcb.138.6.1395. - DOI - PMC - PubMed
1. Schopperle WM, Kershaw DB, DeWolf WC. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun. 2003;300(2):285–290. doi: 10.1016/S0006-291X(02)02844-9. - DOI - PubMed
1. Itai S, Yamada S, Kaneko MK, Sano M, Nakamura T, Yanaka M, et al. Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2. Biochem Biophys Rep. 2018;15:93–96. doi: 10.1016/j.bbrep.2018.07.008. - DOI - PMC - PubMed
1. Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, et al. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer. 2011;105(5):666–672. doi: 10.1038/bjc.2011.295. - DOI - PMC - PubMed

PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets - PubMed (original) (raw)